Skip to main content

Alfons Macaya Ruíz

Institutions of which they are part

Head of group
Pediatric Neurology
Vall Hebron Institut de Recerca

Alfons Macaya Ruíz

Institutions of which they are part

Head of group
Pediatric Neurology
Vall Hebron Institut de Recerca

Projects

Xarxa R+D+I AGAUR - Acuerdo HUB D’INNOVACIÓ PEDIÀTRICA

IP: Alfons Macaya Ruíz
Collaborators: -
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: AGAUR/XARXES/2018/MACAYA
Duration: 09/04/2020 - 31/12/2023

Enfermedades minoritarias causantes de degeneración de ganglios basales en pedriatría: implemementación combinada del análisis genómico y de biomarcadores.

IP: Belen Perez Dueñas
Collaborators: José Antonio Arranz Amo, Josefa Élida Vázquez Méndez, Alfons Macaya Ruíz, Anna Marcé Grau, Clara Carnicer Cáceres, Mireia Del Toro Riera, Ana Felipe Rucián
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI18/01319
Duration: 01/01/2019 - 31/12/2022

Grups de recerca en Neurologia Pediatrica

IP: Alfons Macaya Ruíz
Collaborators: David Gómez Andrés
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2017SGR01710
Duration: 01/01/2017 - 31/12/2020

Implementació de la Medicina Personalitzada basada en la Genòmica en Malalties Minoritàries Neurològiques no Diagnosticades

IP: Alfons Macaya Ruíz
Collaborators: Elena García Arumí, Francina Munell Casadesus, Teresa Vendrell Bayona, Ramon Martí Seves, David Gómez Andrés, Eduardo Fidel Tizzano
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 113977.67
Reference: SLT002/16/00174
Duration: 01/01/2017 - 31/12/2019

Related news

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools.

Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.

Related professionals

Filipa Xavier De Carvalho Negrao Valente

Filipa Xavier De Carvalho Negrao Valente

Research technician
Cardiovascular Diseases
Read more
Maria Lopez Mendoza

Maria Lopez Mendoza

Predoctoral researcher
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Read more
Maria Vidal Burdeus

Maria Vidal Burdeus

Cardiovascular Diseases
Read more
Jesus Corrionero Alegre

Jesus Corrionero Alegre

Multidisciplinary Nursing Research Group
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.